Respiratory Syncytial Virus (RSV) is more than just a common cold—it’s a leading cause of hospitalization in infants and toddlers worldwide, posing a significant threat during their crucial early years. With their immune systems still developing and no prior exposure to RSV, our youngest are at the highest risk.

The CORAL study, underpinned by rigorous Phase I and II research, utilizes a genetically stable, live-attenuated RSV vaccine developed by the US National Institutes of Health (NIH). This approach mirrors the success of established vaccines against diseases like chickenpox and measles, employing a weakened version of the virus to train young immune systems safely and effectively. This Phase III trial builds on promising earlier research, testing the vaccine’s effectiveness when administered alongside routine pediatric vaccines, ensuring they work together in harmony.

Targeted Protection: It focuses on a live-attenuated RSV vaccine, designed to safely introduce the immune system to the virus, mirroring the approach of successful vaccines for diseases like chickenpox and measles.

Harmonious Integration: This research is critical in demonstrating that the RSV vaccine does not interfere with the immune responses elicited by other routine vaccinations—and vice versa.

A Foundation for the Future: Success here could mean a significant stride towards a world where children are protected against a broader range of illnesses, with vaccines that work together more effectively than ever.

We’re looking for families willing to be part of this vital research, helping us protect future generations from RSV.

Inclusion Criteria:

• Healthy infants and toddlers approximately 6 and 12 months of age
• Full-term birth (≥37 weeks of pregnancy)>
• Guardians capable of ensuring participation in all study procedures

Exclusion Criteria:

• Known or suspected immunodeficiencies
• History of severe reactions to vaccines or their components
• Recent receipt of immunosuppressive therapy or certain medications